Engineered immune cells take on lupus and scleroderma in new trial
Disease control
Terminated
This early-stage study is testing a new treatment called RD06-04, which uses a patient's own immune cells modified to target and attack faulty B cells. The goal is to see if it is safe and tolerable for people with active autoimmune diseases like lupus, scleroderma, and Sjögren's…
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 06:15 UTC